Overview

Whether toripalimab plus actinomycin-D as fist-line treatment can achieve a higher complete response rate than actinomycin-D alone.

Whether an equally high cure rate can be achieved by multi-drug chemotherapy as second-line treatment in patients who have failed fist-line treatment with toripalimab plus actinomycin-D.

Participants will be allocated into two groups. Those in experimental group will receive toripalimab plus actinomycin-D, while those in control group will receive actinomycin-D alone. Treatment will be continued until disease progression, unacceptable toxicity, or withdrawal of consent. Treatment will be completed after 3 consolidation cycles.

Eligibility

Inclusion Criteria:

        Diagnosed as GTN: There is a histologic diagnosis of choriocarcinoma or invasive mole.
        Postmolar GTN: The plateau of β-hCG (±10%) lasts for four measurements over a period of 3
        weeks or longer (days 1, 7, 14, 21). There is a rise (>10%) in β-hCG for three consecutive
        weekly measurements over at least a period of 2 weeks or more (days 1, 7, 14). GTN after
        nonmolar pregnancy: There is a rise after decease, or a plateau of β-hCG 4 weeks after
        abortion, ectopic pregnancy, or term delivery. Pregnancy residue or new pregnancy have been
        ruled out.
        Patients with a FIGO score of 5-6. Signed informed consent. No previous immunotherapy,
        chemotherapy, or radiotherapy. Woman aged 18-60 years. Expected survival ≥ 6 months.
        Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 within 7 days before
        first dose.
        The function of vital organs meets the following requirements: hemoglobin ≥90 g/L, absolute
        neutrophil count ≥1·5×109/L, platelets ≥100×109/L; creatinine ≤1·5 × upper limit of normal
        (ULN), urea nitrogen ≤2·5×ULN; total bilirubin ≤1.5×ULN, alanine aminotransferase and
        aspartate aminotransferase ≤2·5×ULN, INR, PT or APTT ≤1.5×ULN, thyroid stimulating hormone
        ≤ULN (if thyroid stimulating hormone is abnormal, normal T3 and T4 can also be acceptable).
        Exclusion Criteria:
        Histologically confirmed placental-site trophoblastic tumor (PSTT) or epithelioid
        trophoblastic tumor (ETT).
        Histologically confirmed primary choriocarcinoma. Other malignancies in the past 3 years.
        Prior systemic anti-cancer treatment, including chemotherapy and radiotherapy. Live
        vaccines injected within 30 days before the first dose of study drug; Systemic immune
        stimulant agent (such as a bacterial or viral vaccine, colony-stimulating factors,
        interferon, interleukin, and combined vaccine) was used 6 weeks before administration or
        within the 5 half-lives of the drug, whichever is shorter.
        Previous treatment with immunotherapy drugs (including antibodies targeting PD-1, PD-L1,
        PD-L2, cytotoxic T-lymphocyte-associated protein 4, T-cell receptor, chimeric antigen
        receptor T-cell therapy, and other immunotherapy).
        Known hypersensitivity or allergy to actinomycin-D, toripalimab or any of their excipients.
        Any active autoimmune disease requiring systemic treatment during the past 2 years.
        History or current status of non-infectious pneumonia requiring steroid treatment.
        Receiving steroid hormones (prednisone dose > 10mg/ day) or other immunosuppressants within
        14 days before enrollment, excluding those on hormone replacement therapy.
        Active infection that requires systemic treatment. Human immunodeficiency virus infection
        or known acquired immunodeficiency syndrome, active hepatitis B, hepatitis C.
        History of psychotropic drug abuse and are unable to withdraw the psychotropic drug, or
        have mental disorders.
        Grade II or higher myocardial ischemia, myocardial infarction or poorly controlled
        arrhythmia (females with QTc interval ≥470 ms); grade III to IV cardiac insufficiency
        according to New York Heart Association (NYHA) criteria, or cardiac color Doppler
        ultrasound evidence of left ventricular ejection fraction <50%; myocardial infarction, NYHA
        grade II or above heart failure, uncontrolled angina, uncontrolled severe ventricular
        arrhythmia, clinically significant pericardial disease, or electrocardiogram suggesting
        acute ischemia or abnormal active conduction system occurring within 6 months before
        enrolment.
        Uncontrollable hypertension (systolic blood pressure ≥140 mmHg or diastolic blood pressure
        ≥90 mmHg, despite with the optimal drug therapy).
        Abnormal coagulation (international normalized ratio >1·5×ULN or prothrombin time >ULN+4
        seconds or activated partial thromboplastin time >1·5×ULN), with bleeding tendency or
        undergoing thrombolysis or anticoagulant therapy.
        History of cerebrovascular accident (including transient ischemic attack, cerebral
        hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism within 3
        months before enrolment.
        Obvious factors affecting oral drug absorption, such as inability to swallow, chronic
        diarrhea and intestinal obstruction, or sinus or perforation of empty organs within 6
        months.
        A history of allogeneic stem cell transplantation or organ transplantation. Other reasons
        as judged by the investigator.